1982
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute
Anderson T, Devita V, Simon R, Berard C, Canellos G, Garvin A, Young R. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute. Cancer 1982, 50: 2708-2721. PMID: 7139564, DOI: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsHistologic typeDiffuse histologic typeComplete responseNational Cancer InstitutePrognostic factorsLymphoma patientsLymphocytic lymphomaCancer InstituteHigh complete response rateDiffuse lymphoma patientsModern radiotherapeutic techniquesNodular lymphocytic lymphomaNodular lymphoma patientsSimilar treatment regimensComplete response rateImportant prognostic factorStage of diseaseCS ICS IIICS IVB symptomsCombination chemotherapyIV patientsHistologic subtypePatient sexChanging patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978.
Grogan T, Berard C, Steinhorn S, Hankey B, Kant J, Miliauskas J, Young R, DeVita V. Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978. Journal Of The National Cancer Institute 1982, 66: 653-65. PMID: 7074636.Peer-Reviewed Original ResearchConceptsResidual Hodgkin's diseaseHodgkin's diseaseVascular invasionTreatment eraCertain histologic typesExtent of diseaseSite of involvementNational Cancer InstituteEffect of treatmentCurative intentLate deathsExtranodal involvementExtranodal spreadPalliative therapyPathologic reviewAnatomic extentComparable incidenceHistologic subtypeHistologic typeInitial diagnosisPathologic findingsHistologic assessmentVascular spreadHistologic appearanceEffect of duration
1976
Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease
Lotz M, Chabner B, Devita V, Johnson R, Berard C. Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease. Cancer 1976, 37: 266-270. PMID: 1247961, DOI: 10.1002/1097-0142(197601)37:1<266::aid-cncr2820370136>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPathological stagingHodgkin's lymphomaNodular lymphomaHepatic biopsyDiffuse lymphomaFirst positive biopsyPercutaneous hepatic biopsyConsecutive untreated patientsBone marrow needle biopsyNegative spleensAbdominal involvementExploratory laparotomyUntreated patientsHepatic involvementWedge biopsyHistologic typeOverall incidenceRappaport classificationAbdominal diseasePositive biopsiesExtramedullary sitesNeedle biopsyUntreated casesPatientsBiopsy
1973
Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival
Young R, Corder M, Berard C, DeVita V. Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival. JAMA Internal Medicine 1973, 131: 446-454. DOI: 10.1001/archinte.1973.00320090136016.Peer-Reviewed Original ResearchHodgkin's diseaseLymphocyte transformationDelayed hypersensitivityFrequency of relapsesSkin test reactivityFive-year followSkin test antigensPeripheral leukocyte culturesRemission durationUntreated patientsImmune alterationsHistologic typeSkin testSystemic symptomsTest reactivityTest antigenLeukocyte culturesDiseaseHypersensitivitySurvivalDinitrochlorobenzeneCourseRelapseMumpsPatients